Breast cancer cells treated with specific Nav1.5 inhibitors or siRNAs show decreased motility and metastatic capacity (Driffort et al., 2014).Therefore, Nav1.5 may be regarded as a promising target for the diagnosis and therapy of breast cancer. Here, SCN5A is linked to breast cancer.